Log in

OTCMKTS:IPHYFInnate Pharma News Headlines

$6.23
0.00 (0.00 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$6.23
Now: $6.23
$6.23
50-Day Range
$5.53
MA: $6.57
$7.07
52-Week Range
$3.70
Now: $6.23
$8.12
VolumeN/A
Average Volume628 shs
Market Capitalization$489.30 million
P/E RatioN/A
Dividend YieldN/A
Beta0.57

Headlines

Innate Pharma (OTCMKTS IPHYF) News Headlines

Source:
DateHeadline
Is Innate Pharma S.A. (IPHA) A Good Stock To Buy?Is Innate Pharma S.A. (IPHA) A Good Stock To Buy?
finance.yahoo.com - May 31 at 1:03 AM
Innate Pharma (OTCMKTS:IPHYF) and INmune Bio (OTCMKTS:INMB) Critical SurveyInnate Pharma (OTCMKTS:IPHYF) and INmune Bio (OTCMKTS:INMB) Critical Survey
www.americanbankingnews.com - May 15 at 10:23 PM
Innate Pharma to Present New Efficacy Data for Monalizumab in Combination With Cetuximab in Head and Neck Cancer at the ASCO20 Virtual Scientific ProgramInnate Pharma to Present New Efficacy Data for Monalizumab in Combination With Cetuximab in Head and Neck Cancer at the ASCO20 Virtual Scientific Program
feeds.benzinga.com - May 14 at 2:15 AM
Innate Pharma (OTCMKTS:IPHYF) Stock Rating Reaffirmed by Kepler Capital MarketsInnate Pharma (OTCMKTS:IPHYF) Stock Rating Reaffirmed by Kepler Capital Markets
www.americanbankingnews.com - May 13 at 6:24 PM
Does Innate Pharma S.A.'s (EPA:IPH) CEO Salary Compare Well With Others?Does Innate Pharma S.A.'s (EPA:IPH) CEO Salary Compare Well With Others?
finance.yahoo.com - May 12 at 8:25 AM
Innate Pharma up 39% premarket on potential use of cancer drug for Covid-19Innate Pharma up 39% premarket on potential use of cancer drug for Covid-19
seekingalpha.com - March 23 at 8:38 AM
Innate Pharma: An Attractive Commercial Stage Oncology Pick For 2020Innate Pharma: An Attractive Commercial Stage Oncology Pick For 2020
seekingalpha.com - February 24 at 7:14 PM
BRIEF-Innate Pharma Says French Regulator Agrees Lacutamab Tellomak Trial Can Resume Recruitment In Sezary Syndrome And Mycosis FungoidesBRIEF-Innate Pharma Says French Regulator Agrees Lacutamab Tellomak Trial Can Resume Recruitment In Sezary Syndrome And Mycosis Fungoides
www.msn.com - January 13 at 8:27 PM
Innate Pharma Provides Update from Regulatory Agencies on Lacutamab TELLOMAK TrialInnate Pharma Provides Update from Regulatory Agencies on Lacutamab TELLOMAK Trial
www.benzinga.com - January 9 at 1:24 AM
Innate Pharmas Filing for Leukemia Drug Accepted in EuropeInnate Pharma's Filing for Leukemia Drug Accepted in Europe
www.msn.com - January 3 at 2:16 PM
Innate Pharmas stock rallies 23% on leukemia drug submission in EuropeInnate Pharma's stock rallies 23% on leukemia drug submission in Europe
www.marketwatch.com - January 2 at 5:11 PM
Why Innate Pharma Shares Are Soaring TodayWhy Innate Pharma Shares Are Soaring Today
www.fool.com - January 2 at 5:11 PM
BRIEF-Innate Pharma Updates On Lacutamab TELLOMAK Phase II TrialBRIEF-Innate Pharma Updates On Lacutamab TELLOMAK Phase II Trial
www.msn.com - December 13 at 10:52 PM
Innate Pharma Provides Update on Lacutamab TELLOMAK TrialInnate Pharma Provides Update on Lacutamab TELLOMAK Trial
www.marketwatch.com - December 13 at 7:50 AM
INNATE PHARMA RELEASES ITS FINANCIAL CALENDAR FOR 2020INNATE PHARMA RELEASES ITS FINANCIAL CALENDAR FOR 2020
www.benzinga.com - December 4 at 1:21 AM
Innate Pharma Certified as a Great Place to Work(R)Innate Pharma Certified as a Great Place to Work(R)
www.marketwatch.com - December 3 at 7:07 AM
Innate Pharma Certified as a Great Place to Work®Innate Pharma Certified as a Great Place to Work®
www.benzinga.com - December 3 at 7:07 AM
Introducing Innate Pharma (EPA:IPH), The Stock That Slid 62% In The Last Three YearsIntroducing Innate Pharma (EPA:IPH), The Stock That Slid 62% In The Last Three Years
finance.yahoo.com - November 18 at 10:45 AM
Innate Pharma third quarter 2019 reportInnate Pharma third quarter 2019 report
www.benzinga.com - November 13 at 1:56 AM
BRIEF-Innate Pharma Announces Preclinical Data Presentations At SITC 2019BRIEF-Innate Pharma Announces Preclinical Data Presentations At SITC 2019
www.msn.com - November 7 at 4:35 AM
Innate Pharma to share new long-term data on Lumoxiti at 2019 American Society of Hematology annual meetingInnate Pharma to share new long-term data on Lumoxiti at 2019 American Society of Hematology annual meeting
www.marketwatch.com - November 7 at 4:35 AM
Innate Pharma announces preclinical data presentations at SITC 2019Innate Pharma announces preclinical data presentations at SITC 2019
www.marketwatch.com - November 6 at 2:15 AM
Innate Pharma Announces Closing of Global OfferingInnate Pharma Announces Closing of Global Offering
www.benzinga.com - October 21 at 5:46 PM
Innate Pharma prices $69M IPOInnate Pharma prices $69M IPO
seekingalpha.com - October 17 at 9:13 AM
Innate Pharma IPO: What You Need To KnowInnate Pharma IPO: What You Need To Know
finance.yahoo.com - October 15 at 7:25 PM
Innate Pharma announces launch of proposed global offering and Nasdaq listingInnate Pharma announces launch of proposed global offering and Nasdaq listing
www.benzinga.com - October 7 at 6:08 AM
Is Innate Pharma (EPA:IPH) Using Too Much Debt?Is Innate Pharma (EPA:IPH) Using Too Much Debt?
finance.yahoo.com - October 3 at 3:46 PM
Innate Pharma announces publication of a review article in NatureInnate Pharma announces publication of a review article in Nature
www.benzinga.com - October 3 at 1:34 AM
Innate Pharma presents early clinical data on IPH5401 and monalizumab at the ESMO 2019 congressInnate Pharma presents early clinical data on IPH5401 and monalizumab at the ESMO 2019 congress
www.marketwatch.com - October 1 at 2:44 AM
Monalizumab to advance to Phase III in head and neck cancerMonalizumab to advance to Phase III in head and neck cancer
www.benzinga.com - September 26 at 3:01 AM
Innate Pharma announces clinical data presentations on IPH5401 and monalizumab at ESMO 2019Innate Pharma announces clinical data presentations on IPH5401 and monalizumab at ESMO 2019
www.benzinga.com - September 23 at 2:30 AM
Innate Pharma files registration statement for proposed initial public offering in the United StatesInnate Pharma files registration statement for proposed initial public offering in the United States
finance.yahoo.com - September 21 at 2:19 AM
Do Institutions Own Shares In Innate Pharma S.A. (EPA:IPH)?Do Institutions Own Shares In Innate Pharma S.A. (EPA:IPH)?
finance.yahoo.com - August 29 at 10:05 PM
Number of shares and voting rights of Innate Pharma as at July 17, 2019Number of shares and voting rights of Innate Pharma as at July 17, 2019
finance.yahoo.com - July 25 at 12:42 PM
Innate Pharma announces publication of IPH4102 Phase I clinical trial results for CTCL in the Lancet OncologyInnate Pharma announces publication of IPH4102 Phase I clinical trial results for CTCL in the Lancet Oncology
feeds.benzinga.com - June 26 at 3:06 AM
Innate Pharma to host key opinion leader call on IPH4102 “TELLOMAK” clinical trial design and rationaleInnate Pharma to host key opinion leader call on IPH4102 “TELLOMAK” clinical trial design and rationale
finance.yahoo.com - June 20 at 10:09 AM
Innate Pharma to host key opinion leader call on IPH4102 "TELLOMAK" clinical trial design and rationaleInnate Pharma to host key opinion leader call on IPH4102 "TELLOMAK" clinical trial design and rationale
feeds.benzinga.com - June 20 at 1:46 AM
INNATE PHARMA: Innate Pharma to present IPH4102 "TELLOMAK" clinical trial design and preclinical PTCL data at the 2019 ICMLINNATE PHARMA: Innate Pharma to present IPH4102 "TELLOMAK" clinical trial design and preclinical PTCL data at the 2019 ICML
www.finanznachrichten.de - June 12 at 1:54 PM
Innate Pharma to present IPH4102 "TELLOMAK" clinical trial design and preclinical PTCL data at the 2019 ICMLInnate Pharma to present IPH4102 "TELLOMAK" clinical trial design and preclinical PTCL data at the 2019 ICML
www.marketwatch.com - June 12 at 1:54 PM
Innate Pharma to present IPH4102 “TELLOMAK” clinical trial design and preclinical PTCL data at the 2019 ICMLInnate Pharma to present IPH4102 “TELLOMAK” clinical trial design and preclinical PTCL data at the 2019 ICML
finance.yahoo.com - June 12 at 1:54 PM
Innate Pharma announces intention to conduct a registered offering in the United StatesInnate Pharma announces intention to conduct a registered offering in the United States
finance.yahoo.com - June 12 at 1:54 PM
Innate Pharma enrolls first patient in IPH4102 TELLOMAK Phase II studyInnate Pharma enrolls first patient in IPH4102 TELLOMAK Phase II study
feeds.benzinga.com - June 6 at 4:32 AM
INNATE PHARMA: Innate Pharma announces publication in Cell on innovative multifunctional NKp46 NK cell engagers (NKCEs)INNATE PHARMA: Innate Pharma announces publication in Cell on innovative multifunctional NKp46 NK cell engagers (NKCEs)
www.finanznachrichten.de - May 31 at 10:33 AM
Innate Pharma announces publication in Cell on innovative multifunctional NKp46 NK cell engagers (NKCEs)Innate Pharma announces publication in Cell on innovative multifunctional NKp46 NK cell engagers (NKCEs)
feeds.benzinga.com - May 31 at 2:55 AM
INNATE PHARMA ANNOUNCES PUBLICATION ON NEXT GENERATION IMMUNOTHERAPIES TARGETING THE ADENOSINE PATHWAY IN "CELL REPORTS"INNATE PHARMA ANNOUNCES PUBLICATION ON NEXT GENERATION IMMUNOTHERAPIES TARGETING THE ADENOSINE PATHWAY IN "CELL REPORTS"
www.marketwatch.com - May 23 at 10:28 AM
Outcome of Annual General Meeting of May 22, 2019Outcome of Annual General Meeting of May 22, 2019
finance.yahoo.com - May 23 at 10:28 AM
Innate Pharma First Quarter 2019 ReportInnate Pharma First Quarter 2019 Report
feeds.benzinga.com - May 15 at 3:16 AM
Innate Pharma to hold its Annual General Meeting of Shareholders on May 22, 2019 and the release of its 2018 Reference Document (in French)Innate Pharma to hold its Annual General Meeting of Shareholders on May 22, 2019 and the release of its 2018 Reference Document (in French)
finance.yahoo.com - May 1 at 10:16 AM
Number of shares and voting rights of Innate Pharma as at April 18, 2019Number of shares and voting rights of Innate Pharma as at April 18, 2019
finance.yahoo.com - April 24 at 10:43 AM
2018 financial results and business update: landmark deal with AstraZeneca to support transition into a fully integrated oncology-focused biotech, strong clinical progress in lead assets2018 financial results and business update: landmark deal with AstraZeneca to support transition into a fully integrated oncology-focused biotech, strong clinical progress in lead assets
finance.yahoo.com - March 20 at 10:09 AM
This page was last updated on 6/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.